ArticleJournal of thoracic disease2026
A layered target-release nanoparticle system for normalizing the lung cancer microenvironment and enhancing antitumor effect.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Abnormal tumor vasculature and dense collagen fiber networks contribute to elevated interstitial pressure in solid tumors, compressing blood vessels and impairing the delivery of nanoparticle (NP)-based therapeutics. Promoting normalization of the tumor microenvironment is a promising strategy for enhancing drug penetration. This study aimed to develop a pH-responsive bilayer nanoplatform capable of sequentially delivering a microenvironment modulator and a targeted chemotherapeutic agent for improved efficacy against lung cancer. Methods: We designed a bilayer lipid NP system with an inner core of triptolide (TPL) encapsulated in folic acid-modified chitosan for tumor cell targeting. The outer layer was composed of pH-sensitive dioleoylphosphatidylethanolamine (DOPE) lipids, co-encapsulated ligustrazine (LT), and TPL-loaded nanoparticles (TPL-NPs) to form LT-co-encapsulated TPL-NPs (LT@TPL-NPs). NP characterization, pH-responsive release profiling, and Results: In the acidic tumor microenvironment, LT@TPL-NPs triggered the sequential release of LT followed by TPL-NPs. LT promoted the normalization of the tumor microenvironment, characterized by reduced interstitial pressure and enhanced NP penetration depth. The released TPL-NPs, modified with folic acid and carrying a positive surface charge, demonstrated efficient cellular uptake and intracellular drug delivery in lung cancer cell models. Conclusions: This pH-responsive bilayer nanoplatform enables spatiotemporally controlled release of a microenvironment-modulating agent and a targeted chemotherapeutic, achieving synergistic effects of physical barrier remodeling and tumor cell cytotoxicity. This strategy offers a potential approach to overcoming delivery barriers in solid tumors and should be further evaluated in preclinical models of thoracic malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.